Kodiak Sciences Inc KOD
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if KOD is a good fit for your portfolio.
News
-
Kodiak Sciences Data at ARVO 2024 Highlight Depth of Early and Late-Phase Retina Pipeline including Advancements with High Drug-Antibody-Ratio Therapeutics Built on Kodiak's Antibody Biopolymer Conjugate (ABC) Platform
-
Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
-
Kodiak Sciences to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Business Updates Webcast on March 28, 2024
-
Kodiak Sciences stock plunges into record-low territory after decision to discontinue wet AMD treatment
Trading Information
- Previous Close Price
- $3.70
- Day Range
- $3.73–4.06
- 52-Week Range
- $1.37–9.80
- Bid/Ask
- $3.80 / $3.90
- Market Cap
- $198.06 Mil
- Volume/Avg
- 305,707 / 807,672
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is KSI-301, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 111
- Website
- https://www.kodiak.com
Comparables
Valuation
Metric
|
KOD
|
IMVT
|
ACLX
|
---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 0.74 | 6.16 | 5.68 |
Price/Sales | — | — | 22.95 |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
Metric
|
KOD
|
IMVT
|
ACLX
|
---|---|---|---|
Quick Ratio | 6.84 | 21.56 | 5.94 |
Current Ratio | 6.93 | 22.14 | 6.06 |
Interest Coverage | −21,323.92 | — | −23.39 |
Quick Ratio
KOD
IMVT
ACLX
Profitability
Metric
|
KOD
|
IMVT
|
ACLX
|
---|---|---|---|
Return on Assets (Normalized) | −29.40% | −43.33% | −6.26% |
Return on Equity (Normalized) | −49.54% | −47.83% | −12.08% |
Return on Invested Capital (Normalized) | −43.67% | −52.69% | −13.11% |
Return on Assets
KOD
IMVT
ACLX
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Wwpxjkvx | Wpyr | $545.9 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Wnnkpqy | Jzpmnt | $105.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Mwybjrfl | Xjcst | $103.7 Bil | |
MRNA
| Moderna Inc | Zjytjgqy | Nbcg | $47.9 Bil | |
ARGX
| argenx SE ADR | Ygfmtwmvb | Vbld | $22.9 Bil | |
BNTX
| BioNTech SE ADR | Dmdndnnrj | Qkktn | $22.3 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Vhbwdmrqr | Yfclcwn | $19.3 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Ppdqmdy | Knjhd | $15.7 Bil | |
RPRX
| Royalty Pharma PLC Class A | Mlpvvfsl | Qqgbby | $12.8 Bil | |
INCY
| Incyte Corp | Dsssyhwq | Cgxnl | $12.1 Bil |